Automatic summarization of medical interviews
Abstract. The genomic-based targeted therapy (Crizotinib) has been emerged as an alternative option for the treatment of patients with locally advanced or metastatic non-small cell lung cancer, comprising the 85\% of lung cancer. However, Crizotinib is not listed in VA drug formulary- and is not ava...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2018-01-01
|
| Series: | MATEC Web of Conferences |
| Online Access: | https://doi.org/10.1051/matecconf/201818907002 |